DISEASE INDICATIONS: Atopic Dermatitis

MANUFACTURER: Leo Pharma

USAGE: Subcutaneous

MEDICINE APPROVED BY:

Food and Drug Administration (FDA)

Adbry (tralokinumab-ldrm) is a biologic medication used to treat moderate to severe eczema in adults by inhibiting the inflammatory protein, interleukin-13. It is administered as a subcutaneous injection, and initial loading doses are followed by maintenance doses every four weeks. Adbry should be stored in a refrigerator, and patients should inform their doctor of any infections or weakened immune systems.